Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tocofersolan + tocopherol alpha is a combination of two forms of vitamin E. Tocofersolan (also known as d-alpha-tocopheryl polyethylene glycol 1000 succinate or TPGS) is a synthetic, water-soluble derivative of natural vitamin E (alpha-tocopherol), designed to enhance the absorption and bioavailability of vitamin E in patients with fat malabsorption disorders such as congenital or hereditary chronic cholestasis[1][2][3][7]. Alpha-tocopherol is the most biologically active form of vitamin E and acts as an antioxidant, protecting cell membranes from oxidative damage[4][8]. The combination provides both immediate antioxidant activity from free alpha-tocopherol and improved absorption via the solubilizing properties of tocofersolan. This formulation may be used in pediatric patients with conditions leading to impaired bile secretion and subsequent fat-soluble vitamin deficiencies. Both components act primarily by scavenging free radicals and inhibiting lipid peroxidation within biological membranes[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tocofersolan + tocopherol alpha.